Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone

Oncology Letters
Matej HorvatBarbara Jezeršek Novaković

Abstract

Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical practice. This single-center, retrospective database analysis included patients with DLBCL treated at the Slovenian Institute of Oncology Ljubljana between 2004 and 2013. Overall survival (OS) and progression-free survival (PFS) were assessed according to International Prognostic Index (IPI) and revised IPI (R-IPI) categories. Overall, 573 patients with DLBCL were included in the study (median follow-up, 45.3 months; range, 0.1-143.0). Patients were categorized as IPI 'low' (n=170; 30%), 'low-intermediate' (n=134; 23%), 'high-intermediate' (n=129; 23%) and 'high' (n=140; 24%) risk. R-IPI groups were indicated with 'very good' (n=59; 10%), 'good' (n=245; 43%) and 'poor' (n=269; 47%) prognosis. Ten-year OS and PFS rates were 51 and 72%, respectively; median OS was 124 months and median PFS was not reached. Ten-year OS rates were 80 and 87% in low-risk and 'very good' prognosis groups, respectively, and 30 and 37% in high-risk and poor prognosis patients, respectively. T...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Oct 19, 2012·Radiology and Oncology·Brigita GregoricBarbara Jezersek Novakovic
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Jan 7, 2015·Cancer Epidemiology·Yang LiShuangge Ma
Jun 10, 2015·Cancer Causes & Control : CCC·Adam J OlszewskiJorge J Castillo
Jul 21, 2015·Nature Medicine·Wyndham H WilsonLouis M Staudt
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H TillyUNKNOWN ESMO Guidelines Committee
Jul 7, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah M StephensSonali M Smith

❮ Previous
Next ❯

Citations

Jun 12, 2020·Therapeutic Advances in Vaccines and Immunotherapy·Leena Halim, John Maher
Sep 26, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hee Sang HwangHeounjeong Go
Mar 11, 2021·Therapeutics and Clinical Risk Management·Barbara Jezeršek NovakovićAleksander Novaković

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02285062
NCT01855750

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.